Mitochondrial Transport Proteins in Cardiovascular Diseases: Metabolic Gatekeepers, Pathogenic Mediators and Therapeutic Targets
Open Access
- 31 August 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8475
Abstract
Mitochondria, as the metabolic hubs of cells, play a pivotal role in maintaining cardiovascular homeostasis through dynamic regulation of energy metabolism, redox balance, and calcium signaling. Cardiovascular diseases (CVDs), including heart failure, ischemic heart disease, cardiomyopathies, and myocardial infarction, remain the leading cause of global mortality, with mitochondrial dysfunction emerging as a unifying pathological mechanism across these conditions. Emerging evidence suggests that impaired mitochondrial transport systems—critical gatekeepers of metabolite flux, ion exchange, and organelle communication—drive disease progression by disrupting bioenergetic efficiency and exacerbating oxidative stress. This review synthesizes current knowledge on mitochondrial transport proteins, such as the voltage-dependent anion channels, transient receptor potential channels, mitochondrial calcium uniporter, and adenine nucleotide translocator, focusing on their structural–functional relationships and dysregulation in CVD pathogenesis. We highlight how aberrant activity of these transporters contributes to hallmark features of cardiac pathology, including metabolic inflexibility, mitochondrial permeability transition pore destabilization, and programmed cell death. Furthermore, we critically evaluate preclinical advances in targeting mitochondrial transport systems through pharmacological modulation, gene editing, and nanoparticle-based delivery strategies. By elucidating the mechanistic interplay between transport protein dysfunction and cardiac metabolic reprogramming, we address a critical knowledge gap in cardiovascular biology and provide a roadmap for developing precision therapies. Our insights underscore the translational potential of mitochondrial transport machinery as both diagnostic biomarkers and therapeutic targets, offering new avenues to combat the growing burden of CVDs in aging populations.Keywords
Funding Information
- National Natural Science Foundation of China (32570908, 32571359, 82470442, 82170429, 2024GZkf-05, B18053)
- Fuwai Hospital, Chinese Academy of Medical Sciences (32570908, 32571359, 82470442, 82170429, 2024GZkf-05, B18053)
- the 111 Project from the Education Ministry of China (32570908, 32571359, 82470442, 82170429, 2024GZkf-05, B18053)
- The 2115 Talent Development Program of China Agricultural University (32570908, 32571359, 82470442, 82170429, 2024GZkf-05, B18053)
This publication has 180 references indexed in Scilit:
- Cardiac Slc25a49 ‐Mediated Energy Reprogramming Governs Doxorubicin‐Induced Cardiomyopathy through the G6P–AP‐1–Sln AxisAdvanced Science, 2025
- Conserved and Unique Mitochondrial Target Sequence of TRPV4 Can Independently Regulate Mitochondrial FunctionsProteins: Structure, Function, and Bioinformatics, 2024
- Nanoparticle‐based therapeutic strategies for mitochondrial dysfunction in cardiovascular diseaseJournal of Biomedical Materials Research Part A, 2024
- Advanced microfluidic devices for fabricating multi‐structural hydrogel microsphereExploration, 2021
- Nanoscale electrodeposition: Dimension control and 3D conformalityExploration, 2021
- Biomimetic assembly to superplastic metal–organic framework aerogels for hydrogen evolution from seawater electrolysisExploration, 2021
- NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implicationsMedicinal Research Reviews, 2021
- ABC Transporters, Cholesterol Efflux, and Implications for Cardiovascular Diseases2020
- Cardiac Sodium Channel Nav1.5 Mutations and Cardiac ArrhythmiaPediatric Cardiology, 2012
- Acute Heart Failure—Basic Pathomechanism and New Drug TargetsHerz, 2006